Bioretec Ltd Successfully Registers New Shares Following Rights Issue Completion

Bioretec Ltd Registers New Shares with Trade Register

Bioretec Ltd, a pioneering company in the field of biodegradable implant technologies, has marked a significant milestone with the registration of new shares following the completion of its rights issue. This strategic financial offering has allowed Bioretec to bring in 1,286,801,534 new shares along with 24,196,337 shares issued to Stephen Industries Inc Oy as an underwriting fee, thus enabling the company to enhance its funding and drive future innovations in orthopedic care.

The official registration took place on April 28, 2026, in Finland, coinciding with the final results announcement of the rights issue earlier on April 24, 2026. As a result, the total number of shares and voting rights in Bioretec now stands at an impressive 1,341,785,963, illustrating a robust increase in its equity capital without any retained shares by the company itself.

These newly registered shares not only serve as a means to raise capital but also maintain the same rights as Bioretec's existing shares once they are delivered to investors’ accounts, expected around April 29, 2026. Trading is projected to commence soon thereafter on the Nasdaq First North Growth Market Finland, pending approval from Nasdaq Helsinki Ltd for the company's listing application.

Pioneering Innovations in Orthopedics

Bioretec Ltd is renowned for its cutting-edge approach to orthopedic care, introducing products that transform patient experiences through fully biodegradable implant technologies. Its flagship innovation, the RemeOs™ product line, crafted from a high-performance magnesium alloy and hybrid composite, greatly enhances surgical outcomes by providing strong absorbable materials. These implants dissolve and are naturally replaced by bone, eliminating the need for additional surgeries and thus facilitating faster recovery.

On an international scale, Bioretec's surgical solutions are already utilized in approximately 40 countries, reflecting the global demand for its advanced orthopedic solutions. The RemeOs line gained market authorization in the U.S. in March 2023, and in Europe, CE mark approval was achieved in January 2025. In addition to RemeOs, the Activa product line further underscores Bioretec's commitment to innovation, offering bioabsorbable orthopedic implants made from proprietary, self-reinforced PLGA, which have received both CE marking and FDA clearance for various uses in adult and pediatric patients.

The Future of Orthopedic Treatment

In a rapidly evolving medical landscape, Bioretec Ltd stands at the forefront of orthopedic device innovation, focusing on absorption healing technologies that promise a more effective and patient-friendly approach to treatment. Their emphasis on biodegradable materials and designs aims to tackle some of the most pressing challenges in orthopedic care, such as the need for surgical removal of implants after the healing process.

As the company positions itself for future developments, the successful execution of the rights issue reflects investor confidence and the potential for growth within the biotech sector. CEO Sarah van Hellenberg Hubar-Fisher and CFO Tuukka Paavola are key figures driving this vision forward, ensuring that Bioretec not only meets the current demands of healthcare providers and patients but also anticipates future needs in orthopedic care.

For more comprehensive insights into Bioretec's offerings and corporate strategies, interested parties can visit www.bioretec.com. With its innovative spirit, Bioretec is steering toward a future marked by sustainable medical solutions and improved patient outcomes.

Conclusion

Overall, the recent registration of new shares signifies a major step in Bioretec's journey toward revolutionizing orthopedic care. With increased funding and a strong focus on research and development, the company is well-equipped to continue its legacy of delivering breakthrough medical technologies that enhance healing processes, setting a new standard in patient care.

This release emphasizes the company’s commitment to transparency and regulatory compliance, clearly stating that it does not constitute an offer for securities in any restricted jurisdictions, addressing potential investors and stakeholders in accordance with governance laws. Bioretec remains poised for continued growth and innovation in the specialized field of orthopedic devices.